The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  García, Samuel ^a   Conde, Carmen ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PARP1 PROTEIN, HUMAN;

ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84939863982     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/837250     Document Type: Review

References (72)

1. M. Feldmann, F. M. Brennan, and R. N. Maini, "Rheumatoid arthritis," Cell, vol. 85, no. 3, pp. 307-310, 1996.
2. G. S. Firestein, "Evolving concepts of rheumatoid arthritis," Nature, vol. 423, no. 6937, pp. 356-361, 2003.
3. Y. Alamanos and A. A. Drosos, "Epidemiology of adult rheumatoid arthritis," Autoimmunity Reviews, vol. 4, no. 3, pp. 130-136, 2005.
4. I. B. McInnes and G. Schett, "The pathogenesis of rheumatoid arthritis," The New England Journal of Medicine, vol. 365, no. 23, pp. 2205-2219, 2011.
5. A. K. Andersson, C. Li, and F. M. Brennan, "Recent developments in the immunobiology of rheumatoid arthritis," Arthritis Research & Therapy, vol. 10, no. 2, article 204, 2008.
6. E. H. Noss and M. B. Brenner, "The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis," Immunological Reviews, vol. 223, no. 1, pp. 252-270, 2008.
7. Z. Szekanecz, T. Besenyei, A. Szentpetery, and A. E. Koch, "Angiogenesis and vasculogenesis in rheumatoid arthritis," Current Opinion in Rheumatology, vol. 22, pp. 299-306, 2010.
8. F. M. Brennan and I. B. McInnes, "Evidence that cytokines play a role in rheumatoid arthritis," The Journal of Clinical Investigation, vol. 118, no. 11, pp. 3537-3545, 2008.
9. I. B. McInnes and G. Schett, "Cytokines in the pathogenesis of rheumatoid arthritis," Nature Reviews Immunology, vol. 7, no. 6, pp. 429-442, 2007.
10. T. Thalhamer, M.A. McGrath, and M. M. Harnett, "MAPKs and their relevance to arthritis and inflammation," Rheumatology, vol. 47, no. 4, pp. 409-414, 2008.
11. G. L. Johnson and R. Lapadat, "Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases," Science, vol. 298, no. 5600, pp. 1911-1912, 2002.
12. G. Schett, M. Tohidast-Akrad, J. S. Smolen et al., "Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-Jun Nterminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis," Arthritis & Rheumatism, vol. 43, no. 11, pp. 2501-2512, 2000.
13. Z. Han, D. L. Boyle, L. Chang et al., "c-Jun N-terminal kinase is required formetalloproteinase expression and joint destruction in inflammatory arthritis," Journal of Clinical Investigation, vol. 108, no. 1, pp. 73-81, 2001.
14. Z. Han, L. Chang, Y. Yamanishi, M. Karin, and G. S. Firestein, "Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passivemurine collagen-induced arthritis," Arthritis and Rheumatism, vol. 46, no. 3, pp. 818-823, 2002.
15. M. Nishikawa, A. Myoui, T. Tomita, K. Takahi, A. Nampei, and H. Yoshikawa, "Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogenactivated protein kinase inhibitor FR167653," Arthritis and Rheumatism, vol. 48, no. 9, pp. 2670-2681, 2003.
16. S. Medicherla, J. Y. Ma, R. Mangadu et al., "A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis," Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 1, pp. 132-141, 2006.
17. H. Okamoto, "Molecular aspects of rheumatoid arthritis: chemokines, environmental factors and transcription factors," FEBS Journal, vol. 275, no. 18, p. 4447, 2008.
18. P. P. Tak and G. S. Firestein, "NF-kappaB: a key role in inflammatory diseases," Journal of Clinical Investigation, vol. 107, pp. 7-11, 2001.
19. R. E. Simmonds and B. M. Foxwell, "Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation," Rheumatology, vol. 47, no. 5, pp. 584-590, 2008.
20. R. Zenz, R. Eferl, C. Scheinecker et al., "Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease," Arthritis Research and Therapy, vol. 10, no. 1, article 201, 2008.
21. J. S. Courtenay, M. J. Dallman, A. D. Dayan, A. Martin, and B. Mosedale, "Immunisation against heterologous type II collagen induces arthritis in mice," Nature, vol. 283, no. 5748, pp. 666-668, 1980.
22. M. Hegen, J. C. Keith Jr., M. Collins, and C. L. Nickerson-Nutter, "Utility of animal models for identification of potential therapeutics for rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 67, no. 11, pp. 1505-1515, 2008.
23. J. A. Luross and N. A. Williams, "The genetic and immunopathological processes underlying collagen-induced arthritis," Immunology, vol. 103, no. 4, pp. 407-416, 2001.
24. K. Terato, K. A. Hasty, R. A. Reife, M. A. Cremer, A. H. Kang, and J. M. Stuart, "Induction of arthritis with monoclonal antibodies to collagen," The Journal of Immunology, vol. 148, no. 7, pp. 2103-2108, 1992.
25. K. S. Nandakumar, J. Bäcklund, M. Vestberg, and R. Holmdahl, "Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells," Arthritis Research & Therapy, vol. 6, no. 6, pp. R544-R550, 2004.
26. D. L. Asquith, A. M. Miller, I. B. McInnes, and F. Y. Liew, "Animal models of rheumatoid arthritis," European Journal of Immunology, vol. 39, no. 8, pp. 2040-2044, 2009.
27. J. Keffer, L. Probert, H. Cazlaris et al., "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis," EMBOJournal, vol. 10, no. 13, pp. 4025-4031, 1991.
28. V. Kouskoff, A.-S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis, "Organ-specific disease provoked by systemic autoimmunity," Cell, vol. 87, no. 5, pp. 811-822, 1996.
29. D. Kyburz and M. Corr, "The KRN mouse model of inflammatory arthritis," Springer Seminars in Immunopathology, vol. 25, no. 1, pp. 79-90, 2003.
30. R. Miesel, M. Kurpisz, and H. Kröger, "Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase," Inflammation, vol. 19, no. 3, pp. 379-387, 1995.
31. H. Kröger, R. Miesel, A. Dietrich, M. Ohde, E. Rajnavölgyi, and H. Ockenfels, "Synergistic effects of thalidomide and poly(ADP-ribose) polymerase inhibition on type II collageninduced arthritis in mice," Inflammation, vol. 20, no. 2, pp. 203-215, 1996.
32. T. Ekblad, E. Camaioni, H. Schüler, and A. Macchiarulo, "PARP inhibitors: polypharmacology versus selective inhibition," FEBS Journal, vol. 280, no. 15, pp. 3563-3575, 2013.
33. J. G. Mabley, P. Jagtap, M. Perretti et al., "Anti-inflammatory effects of a novel, potent inhibitor of poly(ADP-ribose) polymerase," Inflammation Research, vol. 50, no. 11, pp. 561-569, 2001.
34. C. Szabó, L. Virág, S. Cuzzocrea et al., "Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3867-3872, 1998.
35. E. Gonzalez-Rey, R. Martinez-Romero, F. O'Valle et al., "Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response," PLoS One, vol. 2, no. 10, Article IDe1071, 2007.
36. S. García, A. Bodaño, A. González, J. Forteza, J. J. Gómez-Reino, and C. Conde, "Partial protection against collagen antibodyinduced arthritis in PARP-1 deficient mice," Arthritis Research & Therapy, vol. 8, article R14, 2006.
37. E. Mazzon, I. Serraino, J.-H. Li et al., "GPI 6150, a poly (ADPribose) polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation," European Journal of Pharmacology, vol. 415, no. 1, pp. 85-94, 2001.
38. S. García, A. Bodaño, J. L. Pablos, J. J. Gómez-Reino, and C. Conde, "Poly(ADP-ribose) polymerase inhibition reduces tumor necrosis factor-induced inflammatory response in rheumatoid synovial fibroblasts," Annals of the Rheumatic Diseases, vol. 67, no. 5, pp. 631-637, 2008.
39. J. C. Amé, C. Spenlehauer, and G. de Murcia, "The PARP superfamily," BioEssays, vol. 26, no. 8, pp. 882-893, 2004.
40. V. Schreiber, F. Dantzer, J. C. Ame, and G. de Murcia, "Poly (ADP-ribose): novel functions for an old molecule," Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 517-528, 2006.
41. B. C. Woodhouse and G. L. Dianov, "Poly ADP-ribose polymerase-1: an international molecule of mystery," DNA Repair, vol. 7, no. 7, pp. 1077-1086, 2008.
42. A. Bürkle, "Poly(ADP-ribose). Themost elaboratemetabolite of NAD+," FEBS Journal, vol. 272, no. 18, pp. 4576-4589, 2005.
43. M. Y. Kim, T. Zhang, and W. L. Kraus, "Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying'NAD+ into a nuclear signal," Genes and Development, vol. 19, no. 17, pp. 1951-1967, 2005.
44. S. Shall and G. De Murcia, "Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?" Mutation Research, vol. 460, no. 1, pp. 1-15, 2000.
45. P. Jagtap and C. Szabó, "Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors," Nature Reviews Drug Discovery, vol. 4, no. 5, pp. 421-440, 2005.
46. S. H. Snyder, "Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 24, pp. 13978-13982, 1999.
47. C. M. Simbulan-Rosenthal, D. S. Rosenthal, S. Iyer, A. H. Boulares, and M. E. Smulson, "Transient poly(ADP-ribosyl) ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis," The Journal of Biological Chemistry, vol. 273, no. 22, pp. 13703-13712, 1998.
48. F. J. Oliver, G. de la Rubia, V. Rolli, M. C. Ruiz-Ruiz, G. De Murcia, and J. Ménissier-DeMurcia, "Importance of poly(ADPribose) polymerase and its cleavage in apoptosis: lesson froman uncleavable mutant," Journal of Biological Chemistry, vol. 273, no. 50, pp. 33533-33539, 1998.
49. S.-W. Yu, H. Wang, M. F. Poitras et al., "Mediation of poty (ADP-ribose) polymerase-1-dependent cell death by apoptosisinducing factor," Science, vol. 297, no. 5579, pp. 259-263, 2002.
50. S.-W. Yu, S. A. Andrabi, H. Wang et al., "Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18314-18319, 2006.
51. F. J. Oliver, J. Ménissier-deMurcia, C. Nacci et al., "Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly (ADP-ribose) polymerase-1 deficient mice," EMBO Journal, vol. 18, no. 16, pp. 4446-4454, 1999.
52. B. Zingarelli, P. W. Hake, T. J. Burroughs, G. Piraino, M. O'Connor, and A. Denenberg, "Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis," Immunology, vol. 113, no. 4, pp. 509-517, 2004.
53. V. Burkart, Z.-Q. Wang, J. Radons et al., "Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin," Nature Medicine, vol. 5, no. 3, pp. 314-319, 1999.
54. O. Mustapha, R. Datta, K. Oumouna-Benachour et al., "Poly (ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment bymodulating Th2 cytokines in amurinemodel of allergic airway inflammation: a potential specific effect on IL-5," Journal of Immunology, vol. 177, no. 9, pp. 6489-6496, 2006.
55. K. Oumouna-Benachour, C. P. Hans, Y. Suzuki et al., "Poly (ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-κB nuclear translocation, and foam cell death," Circulation, vol. 115, no. 18, pp. 2442-2450, 2007.
56. R. Aguilar-Quesada, J. A. Muñoz-Gámez, D. Martín-Oliva et al., "Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation," Current Medicinal Chemistry, vol. 14, no. 11, pp. 1179-1187, 2007.
57. B. Veres, B. Radnai, F. Gallyas Jr. et al., "Regulation of kinase cascades and transcription factors by a poly(ADP-ribose)polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice," Journal of Pharmacology and Experimental Therapeutics, vol. 310, no. 1, pp. 247-255, 2004.
58. V. Pétrilli, Z. Herceg, P. O. Hassa et al., "Noncleavable poly (ADP-ribose) polymerase-1 requlates the inflammation response in mice," Journal of Clinical Investigation, vol. 114, no. 8, pp. 1072-1081, 2004.
59. D. Martin-Oliva, R. Aguilar-Quesada, F. O'Valle et al., "Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis," Cancer Research, vol. 66, no. 11, pp. 5744-5756, 2006.
60. H. C. Ha, "Defective transcription factor activation for proinflammatory gene expression in poly(ADP-ribose) polymerase 1-deficient glia," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 14, pp. 5087-5092, 2004.
61. Y. Xu, S. Huang, Z.-G. Liu, and J. Han, "Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation," Journal of Biological Chemistry, vol. 281, no. 13, pp. 8788-8795, 2006.
62. B. Racz, K. Hanto, A. Tapodi et al., "Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation," Free Radical Biology and Medicine, vol. 49, no. 12, pp. 1978-1988, 2010.
63. Z. Sarszegi, E. Bognar, B. Gaszner et al., "BGP-15, a PARPinhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38MAP kinases," Molecular and Cellular Biochemistry, vol. 365, no. 1-2, pp. 129-137, 2012.
64. H. Farmer, H. McCabe, C. J. Lord et al., "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy," Nature, vol. 434, no. 7035, pp. 917-921, 2005.
65. H. E. Bryant, N. Schultz, H. D. Thomas et al., "Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase," Nature, vol. 434, pp. 913-917, 2005.
66. A. N. Weaver and E. S. Yang, "Beyond DNA repair: additional functions of PARP-1 in cancer," Frontiers in Oncology, vol. 3, article 290, 2013.
67. N. Curtin, "PARP inhibitors for anticancer therapy," Biochemical Society Transactions, vol. 42, no. 1, pp. 82-88, 2014.
68. N. Schultz, E. Lopez, N. Saleh-Gohari, and T. Helleday, "Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination," Nucleic Acids Research, vol. 31, no. 17, pp. 4959-4964, 2003.
69. S. Nowsheen, T. Cooper, J. A. Bonner, A. F. LoBuglio, and E. S. Yang, "HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair," Cancer Research, vol. 72, no. 18, pp. 4796-4806, 2012.
70. M. Anwar, H. M. Aslam, and S. Anwar, "PARP inhibitors," Hereditary Cancer in Clinical Practice, vol. 13, article 4, 2015.
71. C. J. Lord, A. N. J. Tutt, and A. Ashworth, "Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors," Annual Review of Medicine, vol. 66, no. 1, pp. 455-470, 2015.
72. A. Sonnenblick, E. de Azambuja, H. A. Azim Jr., and M. Piccart, "An update on PARP inhibitors-moving to the adjuvant setting," Nature Reviews Clinical Oncology, vol. 12, no. 1, pp. 27-41, 2014.